Ashley King
Nurse Practitioner · Willoughby, OHNPI 1013455146
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,210 of the $13,177 with a category attached, or 62.3%. Johnson & Johnson accounts for 74.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $10,296 and has fallen 94.0% since, to $621 in 2025. Among nurse practitioner clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $60.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$10K
- AbbVie$854
- Alkermes, Inc.$504
- Indivior Inc.$390
- Lundbeck LLC$347
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$291
- plus $942 from 12 others
What the payments were for
- Speaking & faculty fees$8,21062%
- Travel & lodging$8787%
- Food & beverage$4,08031%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $9,850 |
| AbbVie | 57 | $854 |
| Alkermes, Inc. | 26 | $504 |
| Indivior Inc. | 18 | $390 |
| Lundbeck LLC | 21 | $347 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $291 |
| Otsuka America Pharmaceutical, Inc. | 12 | $246 |
| Abbott | 9 | $213 |
| Sunovion Pharmaceuticals Inc. | 7 | $101 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Braeburn Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Neuronetics, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$9,206
- INVEGA TRINZA$9,088
How this compares
$13,177 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $14,977 |
| BelsomraSuvorexant | 13 | $5,047 |
| Prazosin Hcl | 21 | $283 |
| Hydroxyzine Pamoate | 11 | $172 |
| Fluvoxamine Maleate | 11 | $163 |
| Trazodone Hcl | 16 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $854 | $14,97711 claims |
| MerckBelsomra | $35 | $5,04713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Willoughby
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.